ArticleInfection2026
Prevalence and characterization of West Nile virus infections among people living with HIV in Northern Italy: a sero-repository analysis.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWest Nile virus (WNV) is increasingly reported in Italy, yet its population prevalence remains uncertain. People living with HIV (PLWH) may be at increased risk of WNV severe manifestations, including neuroinvasive disease. This study assessed the seroprevalence and factors associated with WNV seropositivity among PLWH in a large Northern Italian cohort.
methodsThis retrospective single-center study included all PLWH followed at the Brescia HIV Outpatient Clinic with at least one serum sample collected in 2022 and stored in the institutional sero-repository. Samples were screened for WNV antibodies using ELISA; reactive or borderline samples were confirmed by immunofluorescence assay for IgG and IgM and further characterized by microneutralization assays to differentiate WNV from USUV infection. Associations with seropositivity were evaluated using univariate logistic regression.
resultsAmong 2,843 PLWH, 76.2% were male, the mean age was 54.1 (± 10.5), and 87.2% were of Italian origin. Most participants had virologically suppressed HIV infection and were receiving stable antiretroviral therapy (94.2%). WNV serological screening by ELISA identified IgG positivity in 176 participants (6.2%). Of these, 166 tested positive by immunofluorescence assay. Neutralization assays subsequently confirmed WNV seropositivity in 86 participants (3.0%), USUV seropositivity in 12 (0.6%), and dual WNV/USUV neutralizing antibody positivity in 6 (0.2%). No neuroinvasive diseases were reported. Compared with seronegative individuals, seropositive participants were less frequently male (p = 0.001), younger (p < 0.001) and differed significantly by geographic origin (p < 0.001), with a higher prevalence among PLWH born outside Europe. In logistic regression analyses, geographic origin was strongly associated with seropositivity: participants from Africa (OR 21.22, 95% CI 12.49-36.03), Asia (OR = 23.31, 95% CI: 10.19-53.31), and the Americas (OR 19.16, 95% CI 9.45-38.83) had markedly higher odds compared with participants of Italian origin (all p < 0.001). DISCUSSION: This is, to our knowledge, the first study evaluating WNV seroprevalence among PLWH. Seroprevalence was higher than that reported in comparable European blood donor populations. In this largely virologically suppressed, stably treated outpatient cohort, no severe manifestations were observed and symptoms were infrequently recalled.
Indexed as
Identifiers
42579068What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.